Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial data expected in mid-2026 from open ...

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins. While the ...

Following a planned succession process, the Board of Directors of Gubra has appointed Markus Rohrwild as the new CEO of the company effective September 8, 2025. Henrik Blou will step down after almost ...

LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August 21 ...